上海醫藥(02607.HK)與貴州生諾就新型抑酸劑X842項目開展戰略合作
格隆匯10月8日丨上海醫藥(02607.HK)公佈,近日,公司全資子公司上海上藥信誼藥廠有限公司(以下簡稱"上藥信誼")與貴州生諾生物科技有限公司(以下簡稱"貴州生諾")及其全資子公司江蘇太瑞生諾生物醫藥科技有限公司(以下簡稱"江蘇生諾")簽訂《合作協議》,以不超過人民幣(幣種下同)6.9億元(除銷售提成外)的交易金額取得新型抑酸劑X842項目(以下簡稱"X842")原料藥及製劑在中國區域的獨家委託生產和所有適應症的工業銷售權。未來,雙方將進一步探討包括股權投資、聯合開發等形式的合作,加快X842及其他在研產品開發和上市工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.